Altimmune to Participate at Two Upcoming June 2023 Investor Conferences

31 May 2023
www.biospace.com
GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Healthcare Conference in New York, NY Friday, June 9, 2023 Fireside chat at 8:30 am Eastern Time Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA Wednesday, June 14, 2023 Fireside chat at 4:00 pm Pacific Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonistGLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, AltimmuneAltimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit . Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Altimmune Investor & Media Contact: Richard Eisenstadt Chief Financial Officer Phone: 240-654-1450 reisenstadt@altimmune.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.